CYP19A1 and breast cancer: Fat body mass and lean body mass synergistically predict the risk of morphometric vertebral fractures in breast cancer patients who received aromatase inhibitors, a drug commonly used after chemotherapy that may lead to bone loss and elevated fracture risk [44, 45].